期刊
NEUROLOGY
卷 75, 期 3, 页码 230-238出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181e8e8b8
关键词
-
资金
- Alzheimer's Disease Neuroimaging Initiative (ADNI) [U01 AG024904]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Abbott
- AstraZeneca AB
- Bayer Schering Pharma AG
- Bristol-Myers Squibb
- Eisai Global Clinical Development
- Elan Corporation
- Genentech, Inc.
- GE Healthcare
- GlaxoSmithKline
- Innogenetics
- Johnson and Johnson
- Eli Lilly and Co.
- Medpace, Inc.
- Merck and Co., Inc.
- Novartis AG
- Pfizer Inc.
- F. Hoffman-La Roche
- Schering-Plough
- Synarc, Inc.
- Wyeth
- NIH [P30 AG010129, K01 AG030514, NIA 2P30AG10129, NIA R01AG029672, NIA 1U01AG24904, NRCC RL1NS062412, NIA R01AG031252, NIA 9 R01 AG031581-10, 1RC2AG036535-01, NIA U01 AG024904, R01 EB00768, U01 AG10483, NIA R01 AG022394, NINDS T32 NS07222]
- Dana Foundation
- Hillblom Foundation
- Kronos Life Sciences
- AstraZeneca
- Avid Radiopharmaceuticals, Inc.
- State of Arizona
- Eli Lilly and Company
- Baxter Bioscience/ADCS
- Merck Co., Inc.
- Myriad Genetics
- Eisai Inc./ICON Medical Research
- CMS
- University of Pennsylvania
- Donald W. Reynolds Foundation
- Ben B. and Iris M. Margolis Foundation
- Pfizer Inc
- Baxter International Inc.
- Neuro-Hitech
- Martek
- NIH/NIA [U01 AG 06786, P50 AG 16574, U01 AG 024904, R01 AG11378]
- Takeda Pharmaceutical Company Ltd
- US Department of Defense [DAMD17-01-1-0764]
- Veterans Administration [MIRECC VISN 21]
- State of California
- Alzheimer's Association
Objective: A variety of measurements have been individually linked to decline in mild cognitive impairment (MCI), but the identification of optimal markers for predicting disease progression remains unresolved. The goal of this study was to evaluate the prognostic ability of genetic, CSF, neuroimaging, and cognitive measurements obtained in the same participants. Methods: APOE epsilon 4 allele frequency, CSF proteins (A beta(1-42), total tau, hyperphosphorylated tau [p-tau(181p)]), glucose metabolism (FDG-PET), hippocampal volume, and episodic memory performance were evaluated at baseline in patients with amnestic MCI (n=85), using data from a large multisite study (Alzheimer's Disease Neuroimaging Initiative). Patients were classified as normal or abnormal on each predictor variable based on externally derived cutoffs, and then variables were evaluated as predictors of subsequent conversion to Alzheimer disease (AD) and cognitive decline (Alzheimer's Disease Assessment Scale-Cognitive Subscale) during a variable follow-up period (1.9 +/- 0.4 years). Results: Patients with MCI converted to AD at an annual rate of 17.2%. Subjects with MCI who had abnormal results on both FDG-PET and episodic memory were 11.7 times more likely to convert to AD than subjects who had normal results on both measures (p <= 0.02). In addition, the CSF ratio p-tau(181p)/A beta(1-42) (beta = 1.10 +/- 0.53; p = 0.04) and, marginally, FDG-PET predicted cognitive decline. Conclusions: Baseline FDG-PET and episodic memory predict conversion to AD, whereas p-tau(181p)/A beta(1-42) and, marginally, FDG-PET predict longitudinal cognitive decline. Complementary information provided by these biomarkers may aid in future selection of patients for clinical trials or identification of patients likely to benefit from a therapeutic intervention. Neurology (R) 2010;75:230-238
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据